Quote | Adagene Inc. (NASDAQ:ADAG)
Last: | $2.90 |
---|---|
Change Percent: | 0.0% |
Open: | $2.99 |
Close: | $2.90 |
High: | $3.05 |
Low: | $2.88 |
Volume: | 5,291 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
News | Adagene Inc. (NASDAQ:ADAG)
SAN DIEGO and SUZHOU, China, May 22, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its participation in multiple investor conferences in June 20...
BioHarvest Sciences Inc (CNVCF) is expected to report for quarter end 2023-12-31 QS Energy Inc (QSEP) is expected to report for Q4 2023 NKGen Biotech Inc. (NKGN) is expected to report for Q4 2023 Cal-Maine Foods Inc. (CALM) is expected to report for Q3 2024 Davide Campari (DVDCF) ...
Message Board Posts | Adagene Inc. (NASDAQ:ADAG)
Subject | By | Source | When |
---|---|---|---|
good read | StockLogistics | investorshub | 04/25/2023 2:13:05 AM |
$ADAG what do you make of this data? | StockLogistics | investorshub | 04/24/2023 6:53:50 PM |
here we go bulls news is here | StockLogistics | investorshub | 04/23/2023 3:30:57 PM |
$ADAG Price trading | StockLogistics | investorshub | 04/23/2023 11:57:58 AM |
$ADAG must see | StockLogistics | investorshub | 04/23/2023 5:39:07 AM |
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO and SUZHOU, China, May 22, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its participation in multiple investor conferences in June 20...
BioHarvest Sciences Inc (CNVCF) is expected to report for quarter end 2023-12-31 QS Energy Inc (QSEP) is expected to report for Q4 2023 NKGen Biotech Inc. (NKGN) is expected to report for Q4 2023 Cal-Maine Foods Inc. (CALM) is expected to report for Q3 2024 Davide Campari (DVDCF) ...
- Data for masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) highlight best-in-class therapeutic index and demonstrate clinical benefits in metastatic microsatellite-stable (MSS) colorectal cancer (CRC) with higher, more frequent and repeat dosing of anti-CTLA-4 therapy in com...